In this week’s View, Dr. Eagle discusses Lp(a) as a main driver for the risk of ASCVD, MI, and aortic valve stenosis independent of CRP. This article is timely as we continue to attempt to lower the risks with ongoing trials currently working on relevant therapeutic options for lowering Lp(a).
Then Dr. Eagle looks at women with CHD and mild PH who appear to have better pregnancy outcomes as compared with those with moderate-to-severe PH.
Finally, Dr. Eagle explores the PARTNER Trials and its insights concerning cardiac damage and quality of life after Aortic Valve Replacement.
We are looking forward to continuing to engage you during ACC.23 (March 4-6) in this formidable time of education! Check back for further updates!